Impact of the obesity epidemic on hypertension and renal disease

Current Hypertension Reports

Volumn 5, Issue 5, 2003, Pages 386-392

  Hall, John E ^a   Jones, Daniel W ^b   Kuo, Jay J ^b   da Silva, Alexandre ^b   Tallam, Lakshmi S ^b   Liu, Jiankang ^b  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; PROOPIOMELANOCORTIN; SIBUTRAMINE; TETRAHYDROLIPSTATIN; LEPTIN;

ADRENERGIC SYSTEM; BLOOD PRESSURE REGULATION; BODY MASS; CALORIC INTAKE; CARDIOVASCULAR RISK; CELL FUNCTION; DIET RESTRICTION; DISEASE EXACERBATION; ENERGY EXPENDITURE; ESSENTIAL HYPERTENSION; GLOMERULUS FILTRATION RATE; HEREDITY; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY TUBULE ABSORPTION; MOLECULAR MECHANICS; NATRIURESIS; NEPHRON; OBESITY; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK FACTOR; SODIUM ABSORPTION; WEIGHT GAIN; WEIGHT REDUCTION; ANIMAL; BLOOD; HYPERTENSION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; HUMANS; HYPERTENSION; KIDNEY DISEASES; LEPTIN; OBESITY; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM;

EID: 0642312274     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-003-0084-z     Document Type: Review

References (49)

1. Hall JE, Jones DW: What can we do about the obesity epidemic? Am J Hypertens 2002, 15:657-665.
2. Sorof J, Daniels S: Obesity hypertension in children - a problem of epidemic proportions. Hypertension 2002, 40:441-447.
3. Flegal KM, Carroll MD, Ogden CL, Johnson CCL: Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002, 288:1723-1727.
4. Ogden CL, Flegal KM, Carroll MD, Johnson CL: Prevalence and trends in overweight among US children and adolescents. JAMA 2002, 288:1728-1732.
5. Wilson PWF, D'Agostino RB, Sullivan L, et al.: Overweight and obesity as determinants of cardiovascular risk - the Framingham experience. Arch Intern Med 2002, 162:1867-1872.
6. Hall JE, Crook ED, Jones DW, et al.: Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci 2002, 324:127-137.
7. Hall JE, Kuo JJ, Silva A, et al.: Obesity, hypertension and renal disease. Curr Opin Nephrol Hypertens 2003, 12:195-200.
8. Wannamethee SG, Shaper AG: Weight change and duration of overweight and obesity in the incidence of type 2 diabetes. Diabetes Care 1999, 22:1266-1272.
9. Sundquist J, Winkeby MA, Pudaric S: Cardiovascular disease risk factors among older black, Mexican-American, and white women and men: an analysis of NHANES III; 1988-1994. J Am Geriatr Soc 2001, 49:109-116.
10. He Q, Ding YZ, Fong DY, Karlberg J: Blood pressure is associated with body mass index in both normal and obese children. Hypertension 2000, 36:165-170.
11. Garrison RJ, Kannel WB, Stokes J, et al.: Incidence and precursors of hypertension in young adults: The Framingham Offspring Study. Prev Med 1987, 16:235-251.
12. Hall JE, Jones DW, Henegar J, et al.: Obesity hypertension, and renal disease. In Obesity: Mechanisms and Clinical Management. Edited by Eckel RH. Philadelphia: Lippincott, Williams & Wilkins; 2003:273-300.
13. Cooper RS, Potimi CN, Ward R: The puzzle of hypertension in African-Americans. Sci Am 1999, 280:56-63.
14. He J, Whelton PK, Appel LJ, et al.: Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension 2001, 35:544-549.
15. Miller ER, Erlinger TP, Young DR, et al.: Results of the diet, exercise, and weight loss intervention trial (DEW-IT). Hypertension 2002, 40:612-618.
16. Dobrian AD, Davies MJ, Schriver SD, et al.: Oxidative stress in a rat model of obesity-induced hypertension. Hypertension 2001, 37:554-560.
17. Hall JE: The kidney, hypertension, and obesity. Hypertension 2003, 41:625-633.
18. Hall JE, Hildebrandt DA, Kuo J: Obesity hypertension: role of leptin and the sympathetic nervous system. Am J Hypertens 2001, 14:103S-115S.
19. Esler M, Rumantir M, Wiesner G, et al.: Sympathetic nervous system and insulin resistance: from obesity to diabetes. Am J Hypertens 2001, 14:304S-309S.
20. Abate NI, Mansour YH, Arbique D, et al.: Overweight and sympathetic activity in black Americans. Hypertension 2001, 38:379-383.
21. Wofford MR, Anderson DC, Brown CA, et al.: Antihypertensive effect of alpha and beta adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens 2001, 14:694-698.
22. Kassab S, Kato T, Wilkins C, et al.: Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension 1995, 25:893-897.
23. Grassi G, Seravalle G, Dell'Oro R, et al.: Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension 2000, 36:538-542.
24. Weyer C, Pratley RE, Snitker S, et al.: Ethnic differences in insulinemia and sympathetic tone as links between obesity and blood pressure. Hypertension 2000, 36:531-537.
25. Alvarez GE, Beske SD, Ballard TP, Davy KP: Sympathetic neural activation in visceral obesity. Circulation 2002, 106:2533-2536.
26. Grassi G, Seravalle G, Dell'Oro R, et al.: Participation of the hypothalamus-hypophysis axis in the sympathetic activation of human obesity. Hypertension 2001, 38:1316-1320.
27. Eikelis N, Schlaich M, Aggarwal A, et al.: Interactions between leptin and the human sympathetic nervous system hypertension. Hypertension 2003, 41:1072-1079.
28. Jequier E: Leptin signaling, adiposity, and energy balance. Ann N Y Acad Sci 2002, 967:379-388.
29. Correia MLG, Morgan DA, Sivitz WI, et al.: Leptin acts in the central nervous system to produce dose-dependent changes in arterial pressure. Hypertension 2001, 37:936-942.
30. Shek EW, Brands MW, Hall JE: Chronic leptin infusion increases arterial pressure. Hypertension 1998, 31:409-414.
31. Kuo JJ, Jones OB, Hall JE: Inhibition of NO synthesis enhances chronic cardiovascular and renal actions of leptin. Hypertension 2001, 37:670-676.
32. Carlyle M, Jones OB, Kuo JJ, Hall JE: Chronic cardiovascular and renal actions of leptin-role of adrenergic activity. Hypertension 2002, 39:496-501.
33. Aizawa-Abe M, Ogawa Y, Mazuzaki H, et al.: Pathophysiological role of leptin in obesity related hypertension. J Clin Invest 2000, 105(9):1243-1252.
34. Mark AL, Shaffer RA, Correia ML, et al.: Contrasting blood pressure effects of obesity in leptin-deficient ob/ob mice and agouti yellow mice. J Hypertens 1999, 17:1949-1953.
35. Ozata M, Ozdemir IC, Licinio J: Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab 1999, 10:3686-3695.
36. Haynes WG, Morgan DA, Djalali A, et al.: Interactions between the melanocortin system and leptin in control of sympathetic nerve traffic. Hypertension 1999, 33:542-547.
37. Kuo JJ, Silva AA, Hall JE: Hypothalamic melanocortin receptors and chronic regulation of arterial pressure and renal function. Hypertension 2003, 41:768-774.
38. Sharma AM, Janke J, Gorzelniak K, et al.: Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002, 40:609-611.
39. Reisen E, Weir M, Falkner B, et al.: Lisinopril versus hydrochlorothiazide in obese hypertensive patients: A Multicenter Placebo-Controlled Trial. Hypertension 1997, 30:140-145.
40. Zanella MT, Kohlmann Jr O, Ribeiro AB: Treatment of Obesity Hypertension and Diabetes Syndrome. Hypertension 2001, 38:705-708.
41. Morales E, Valero MA, Leon M, et al.: Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003, 41:319-327.
42. Kambham N, Markowitz GS, Valeri AM, et al.: Obesity related glomerulopathy: an emerging epidemic. Kidney Int 2001, 59:1498-1509.
43. Henegar JR, Bigler SA, Henegar LK, et al.: Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 2001, 12:1211-1217.
44. Assmann G, Schulte H: The Prospective Cardiovascular Munster Study (PROCAM): prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary artery disease. Am Heart J 1988, 1116:1713-1724.
45. Praga M, Hernandez E, Herrero JC, et al.: Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. Kidney Int 2000, 58:2111-2118.
46. Stern JS, Gades MD, Wheeldon CM, Borchers AT: Calorie restriction in obesity: prevention of kidney disease in rodents. J Nutr 2001, 131:913S-917S.
47. National Institutes of Health Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. 1998. National Heart, Lung, and Blood Institute and National Institute of Diabetes and Digestive and Kidney Diseases. http://www.nhlbi.nih.gov/guidelines/index.htm. Accessed July, 2003.
48. Sharma AM, Pischon T, Engeli S, et al.: Choice of drug treatment for obesity-related hypertension: where is the evidence? J Hypertens 2001, 19:667-674.
49. Oparil S: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): practical implications. Hypertension 2003, 41:1006-1009.